However, the application of these compounds in breast cancer therapy to date is highly limited and the majority of these therapeutic approaches have focussed entirely on HIF-1 inhibition, with the efficacy of HIF-2 inhibition being largely limited to renal cell carcinoma [69–72]. Here, HIF1A is linked to renal cell carcinoma.